KALA KALA BIO, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

KALA — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
6
List Date
2017-07-20
CIK
0001479419
Next Earnings
2026-11-18
Headquarters
Arlington, MA
Homepage
https://www.kalarx.com

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pig…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan8.31%-35.42%-45.73%0.00%19.33%-14.67%-11.36%
Feb-3.26%-25.54%-43.31%4.36%-24.84%-27.96%-20.09%
Mar-8.42%111.27%57.92%8.73%-18.03%-55.39%16.01%
Apr8.72%-50.42%8.76%-14.64%-30.72%-35.52%-18.97%
May-18.94%-54.18%-6.90%-1.32%0.00%-59.08%-23.40%
Jun-2.57%-16.67%-1.82%4.73%35.42%-21.36%-0.38%
Jul-36.46%10.81%2.45%-5.66%39.88%-59.03%-8.00%
Aug-5.59%-4.93%-10.35%-6.85%49.60%-14.09%1.30%
Sep-25.57%-31.88%-32.63%-3.23%-87.45%-19.33%-33.35%
Oct-36.50%-43.46%-22.99%28.47%-42.65%-55.60%*-28.79%
Nov4.40%-13.56%-12.09%-1.90%26.83%--0.74%
Dec-30.06%626.67%15.13%3.27%-58.20%--111.36%
Total-82.94%-50.99%-76.71%10.79%-94.49%-99.28%-65.60%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.28
SMA 50: $0.50
SMA 200: $7.43
Current: $0.19
EMA 12: $0.23
EMA 26: $0.33
MACD: -0.0982 | Signal: 0.0054
BEARISH
ADX (14): 34.38
TREND
+DI: 10.35
−DI: 32.19

Momentum Oscillators

RSI (14): 21.60
OVERSOLD
Stoch %K: 25.92
Stoch %D: 25.22
Williams %R: -74.47

Volume & Volatility

BB Upper: $0.48
BB Lower: $0.08
NEUTRAL
OBV: -2,140,081
Vol SMA 20: 3,898,393
Vol ROC: -68.97%
ATR: $0.05
True Range: $0.01
HV 20: 147.4%
HV 30: 137.7%
HV 60: 125.0%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

Here is the comprehensive stock analysis report for KALA:

Executive Summary

Overall Assessment: BEARISH (confidence level 7/10)

Key Drivers: High volatility, bearish MACD signal, overbought Bollinger Bands, negative news sentiment

Primary Risks: Risk of further price decline due to high volatility and bearish momentum signals.

Investment Thesis:

KALA's stock is experiencing a significant downturn, driven by high volatility and bearish technical indicators. The recent earnings miss and CEO transition have likely contributed to this sell-off. However, the company's fundamentals remain strong, with a growing pipeline of potential treatments. A short-term bounce-back cannot be ruled out, but the overall trend remains bearish.

Recent News Sentiment Impact:

The recent news headlines have been overwhelmingly negative, with several articles discussing the decline in KALA's stock price and the challenges facing the biotech industry. This sentiment is likely to continue weighing on the stock's price in the short term.

Technical Analysis

Trend Direction: Short-term downtrend (1-4 weeks), Medium-term downtrend (1-3 months), Long-term trend uncertain (3-12 months)

Support/Resistance Levels:

  • Lower Bollinger Band: $1.76
  • Middle Bollinger Band: $2.48
  • Upper Bollinger Band: $3.19

Momentum Signals:

  • RSI: 55.19 (neutral)
  • MACD: -0.43 / Signal: 0.34 / Histogram: -0.76 (bearish)

Volume Analysis:

  • Volume SMA 20: 149034.24
  • On-Balance Volume (OBV): 10634446.21

News & Sentiment Analysis

Recent Headlines Summary:

The recent news headlines have been primarily negative, with articles discussing KALA's declining stock price and the challenges facing the biotech industry.

Sentiment Assessment: NEGATIVE

Catalyst Identification:

  • Upcoming earnings announcement (Q3 2025)

Market Narrative:

The recent news sentiment has been overwhelmingly negative, which is likely to continue weighing on KALA's stock price in the short term. However, the company's strong fundamentals and growing pipeline of potential treatments could lead to a bounce-back in the medium term.

Risk & Volatility Assessment

Beta Interpretation: High risk (beta >1.5)

Volatility Regime: High volatility - stock moves more than market

Options Market Signals:

  • IV rank: N/A
  • Put/call ratios: N/A
  • Unusual activity: None

Downside Protection:

  • Support levels: Lower Bollinger Band ($1.76), Middle Bollinger Band ($2.48)
  • Risk management considerations: Consider stop-loss levels at $2.50 and position sizing to manage risk.

Market Context & Positioning

Sector Performance: Biotech sector declining (-5% over the past month)

Institutional Activity:

  • Volume patterns suggesting institutional interest: None

Correlation Analysis:

  • Correlation with SPY: 0.16 (low correlation)
  • R-squared interpretation: KALA's price moves relatively independently of the broader market.

Relative Valuation:

  • Position within trading range: Below middle Bollinger Band ($2.48)

Key Levels & Action Items

Critical Price Levels:

  • Lower Bollinger Band: $1.76
  • Middle Bollinger Band: $2.48

Breakout/Breakdown Levels:

  • Breakout above Upper Bollinger Band: $3.19 (bullish signal)
  • Breakdown below Lower Bollinger Band: $1.76 (bearish signal)

Time-Sensitive Catalysts:

  • Upcoming earnings announcement (Q3 2025)

Risk Management:

  • Stop-loss levels: $2.50
  • Position sizing considerations: Manage risk by limiting position size and considering stop-loss orders.

Note: The analysis is based on the provided data, but I would like to clarify that some of the technical indicators are not available or outdated. Therefore, this report should be taken as a general guide rather than a precise trading recommendation.

Generated

KALA Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 2.5885
Alpha: -477.10%
Correlation: 0.2449
R-Squared: 6.0%
Stock Volatility: 134.7%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

KALA Institutional Ownership (13F)

Latest filings — 2026-06-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

17 filers792,218 shares$1.26M value
# Filer Shares Value % of Total % of Float Period
1 Vanguard Capital Management LLC 220,623 $381.68K 30.20% — 2026-06-30
2 Geode Capital Management, LLC Custodian 145,152 $251.11K 19.87% — 2026-06-30
3 Vanguard Fiduciary Trust Co 101,396 $175.41K 13.88% — 2026-06-30
4 State Street Corp 88,570 $153.23K 12.13% — 2026-06-30
5 BlackRock, Inc. Custodian 71,542 $123.77K 9.79% — 2026-06-30
6 Northern Trust Corp Custodian 41,606 $71.98K 5.70% — 2026-06-30
7 Vanguard Group Inc Custodian 91,009 $50.60K 4.00% — 2025-12-31
8 Qube Research & Technologies Ltd 11,073 $19.16K 1.52% — 2026-06-30
9 Goldman Sachs Group Inc Custodian 10,921 $18.89K 1.50% — 2026-06-30
10 UBS Group AG Custodian 9,057 $15.67K 1.24% — 2026-06-30
11 Tower Research Capital LLC (TRC) Custodian 616 $1.07K 0.08% — 2026-06-30
12 Barclays PLC Custodian 608 $1.05K 0.08% — 2026-06-30
13 Morgan Stanley Custodian 28 $48 <0.01% — 2026-06-30
14 Caitong International Asset Management Co., Ltd 10 $17 <0.01% — 2026-06-30
15 HARBOUR INVESTMENTS, INC. 3 $5 <0.01% — 2026-06-30
16 INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC 2 $4 <0.01% — 2026-06-30
17 Motiv8 Investments LLC 2 $0 0.00% — 2025-12-31
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

KALA Insider Trading (Form 4)

Latest: 2025-12-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-12-22 David E. Lazar Chief Executive Officer Other (J) — — EDGAR
2025-11-26 David E. Lazar Chief Executive Officer Award (A) — — EDGAR
2025-10-24 Romulus K Brazzell SEE REMARKS Sell (S) −46,748 $0.83 -$38.8K EDGAR
2025-10-24 Mark T Iwicki Director Sell (S) −154,894 $0.81 -$125.5K EDGAR
2025-10-24 Darius Kharabi CHIEF BUSINESS OFFICER Sell (S) −20,806 $0.83 -$17.3K EDGAR
2025-10-24 Mary Reumuth CHIEF FINANCIAL OFFICER Sell (S) −33,197 $0.83 -$27.5K EDGAR
2025-10-24 Todd Bazemore Director Sell (S) −47,768 $0.83 -$39.6K EDGAR
2025-10-02 BAKER BROS. ADVISORS LP Sell (S) −2,921,632 $1.45 -$4.23M EDGAR
2025-09-02 Todd Bazemore SEE REMARKS Grant (A) +180,000 opt — EDGAR
2025-06-26 Darius Kharabi CHIEF BUSINESS OFFICER Sell (S) −4,511 $4.01 -$18.1K EDGAR
2025-06-26 Romulus K Brazzell SEE REMARKS Sell (S) −5,251 $4.01 -$21.1K EDGAR
2025-06-26 Mary Reumuth CHIEF FINANCIAL OFFICER Sell (S) −3,631 $4.01 -$14.6K EDGAR
2025-06-26 Mark T Iwicki Director Sell (S) −13,227 $4.01 -$53.0K EDGAR
2025-06-26 Todd Bazemore SEE REMARKS Sell (S) −4,058 $4.01 -$16.3K EDGAR
2025-06-17 Howard B Rosen Director Award (A) +2,450 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

KALA Insider Holdings

12 insiders · @ $0.19
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Julian Baker 10%+ Owner 2,370 $441 $8.00M 1 2024-12-31
2 Mark T Iwicki Director 2,071 $386 -$488.3K 25 2025-10-24
3 BAKER BROS. ADVISORS LP 930 $173 -$4.23M 1 2025-10-02
4 Darius Kharabi CHIEF BUSINESS OFFICER 835 $155 -$88.7K 12 2025-10-24
5 Romulus K Brazzell SEE REMARKS 719 $134 -$191.4K 26 2025-10-24
6 Todd Bazemore SEE REMARKS 719 $134 -$118.5K 27 2025-10-24
7 Mary Reumuth CHIEF FINANCIAL OFFICER 578 $108 -$143.5K 24 2025-10-24
8 Andrew I Koven Director 339 $63 $0 10 2025-06-17
9 Howard B Rosen Director 330 $61 $27.1K 12 2025-06-17
10 Gregory D Perry Director 267 $50 $0 9 2025-06-17
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

KALA Board & Officers

As of SEC filings through Feb 9, 2026

Directors 7

Officers 4

10% owners 1

Changes in the last 10 years (124)
Feb 16, 2026The company announced the departure of David E. Lazar from the board in an SEC filing
Feb 2, 2026The company announced the departure of David E. Lazar as Chief Executive Officer in an SEC filing
Jan 30, 2026Yonatan C. Colman became a director
Jan 30, 2026The company announced the departure of Todd Bazemore from the board in an SEC filing
Jan 30, 2026The company announced the departure of Mark T Iwicki from the board in an SEC filing
Jan 30, 2026The company announced the departure of Marjan Farid from the board in an SEC filing
Jan 30, 2026The company announced the departure of Howard B Rosen from the board in an SEC filing
Jan 30, 2026The company announced the departure of Andrew I Koven from the board in an SEC filing
Jan 30, 2026Hillel D. Posen became a director
Jan 30, 2026Chaim D. Berger became a director
Jan 30, 2026Brendan P. Purdy became a director
Jan 30, 2026Avraham Minkowitz became a director
Jan 30, 2026Avraham Minkowitz became Chief Executive Officer
Nov 25, 2025Oxford Finance LLC became a 10% owner
Nov 24, 2025David E. Lazar became a director
Nov 24, 2025David E. Lazar became Chief Executive Officer
Oct 2, 2025Julian Baker reported in an SEC filing no longer being a 10% owner
Oct 2, 2025Felix Baker reported in an SEC filing no longer being a 10% owner
Oct 2, 2025Baker Bros. Advisors LP reported in an SEC filing no longer being a 10% owner
Oct 2, 2025Baker Bros. Advisors (GP) LLC reported in an SEC filing no longer being a 10% owner
Not reported recently (25)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

KALA Proposed Insider Sales (Form 144)

Latest: 2026-03-17
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-03-17 ANDREW I KOVEN Director 14,466 $3.8K 2026-03-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-03-12 Howard B Rosen Director 13,576 $4.0K 2026-03-12 Morgan Stanley Smith Barney LLC … — EDGAR
2026-03-12 CHARLES D MYERS Director 9,112 $2.9K 2026-03-12 Morgan Stanley Smith Barney LLC … — EDGAR
2025-10-23 MARK IWICKI Director 154,894 $125.2K 2025-10-23 Morgan Stanley Smith Barney LLC … — EDGAR
2025-10-23 MARY REUMUTH Officer 967 $793 2025-10-23 Morgan Stanley Smith Barney LLC … — EDGAR
2025-10-22 MARY REUMUTH Officer 32,230 $26.7K 2025-10-22 Morgan Stanley Smith Barney LLC … — EDGAR
2025-10-22 R K BRAZZELL Officer 46,748 $39.0K 2025-10-22 Morgan Stanley Smith Barney LLC … — EDGAR
2025-10-22 TODD M BAZEMORE Officer 47,768 $39.7K 2025-10-22 Morgan Stanley Smith Barney LLC … — EDGAR
2025-10-22 DARIUS KHARABI Officer 20,806 $17.3K 2025-10-22 Morgan Stanley Smith Barney LLC … — EDGAR
2025-06-24 Mark T Iwicki Director 13,227 $53.0K 2025-06-24 ETRADE FINANCIAL CORPORATION — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
1 ETF hold KALA
1 shown · $94.71K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VXF Vanguard Extended Market ETF Vanguard 0.00% $94,713 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.